Caleco Pharma Corp. Announces Appointment of Jim Metropoulos MD to Advisory Board

BELLINGHAM, WASHINGTON, Nov 12 (MARKET WIRE) --
Caleco Pharma Corp. (OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) (the
"Company") is pleased to announce that it has appointed Jim Metropoulos,
MD, to the Company's Product Development Advisory Board. The Company's
Product Development Advisory Board is responsible for guiding the
development of the Company's consumer OTC and prescription products from
research stages through commercialization, including the design of
appropriate clinical trails and the selection of clinical sites and
research partners.

Dr. Metropoulos has served as a senior executive in healthcare
communications and product commercialization for over 17 years. Dr.
Metropoulos initially served as Chief Strategic Officer for Lowe McAdams
Healthcare Worldwide where he was responsible for overseeing the
development of comprehensive strategic communications plans for all
clients including the integration of Internet, managed care and consumer
communications with professional advertising and promotion programs. From
2002 to 2006, Dr. Metropoulos served as Co-President; US Operations for
Sudler & Hennessey, a healthcare focused division of the WPP Group.
During this time, Dr. Metropoulos was a leader in integrating
pre-approval research and post-commercialization observational registries
with global communications. Dr. Metropoulos also served as President and
CEO of Euro RSCG Life Worldwide a global healthcare communications
network and a part of the Havas Group. Dr. Metropoulos is the co-founder
of The Rearden Health Partnership, a communications technology, services
and media consulting group with offices in New York, New Jersey and
Paris. The Partnership designs and develops proprietary communications
software platforms for use in education, promotion and product
development. Rearden owns and operates private content distribution
networks linking healthcare professionals and consumers with healthcare
product manufacturers and offers clients a full suite of content
development services including advertising, promotional education,
internet and managed markets communications.

About Caleco Pharma Corp.

The Company's business plan is to develop its proprietary technology
designed to treat moderate to severe liver maladies, including Hepatitis
C viral infection, (the "Liver Health Formula") as an over-the-counter
medication and as a United States Food and Drug Administration ("FDA")
approved pharmaceutical. To date, the Company's intellectual property
covering the Liver Health Formula is comprised of patent applications in
the United States, Europe and Canada and four European Drug Master File
applications.

Caleco Pharma Corp. shares are traded in the United States on the OTC
Bulletin Board (OTCBB: CAEH) and in Germany on the Frankfurt Stock
Exchange (FRANKFURT: T3R)(WKN: A0N9Y0).

This press release may contain, in addition to historic information,
forward-looking statements. These statements may involve known and
unknown risks and uncertainties and other factors that may cause the
actual results to be materially different from the results implied
herein. In particular, there are no assurances that: (i) the United
States Patents and Trademarks Office will grant the Company a patent in
connection with its current patent applications; (ii) the Company will be
able to manufacture and produce its products or that its products will be
effective; or (iii) it will be able to carry out any pre-clinical or
clinical trials of its products. Readers are cautioned not to place undue
reliance on the forward-looking statements made in this press release.

Caleco Pharma Corp.

John Boschert, President

Contacts:
Caleco Pharma Corp.
John Boschert
President
(360) 306-1133
www.calecopharmacorp.com

Copyright 2009, Market Wire, All rights reserved.

-0-